RFP-Tag Polyclonal Antibody

What is an RFP-tag antibody and what variants can it detect?

RFP-tag antibodies are immunoglobulins designed to recognize Red Fluorescent Protein (RFP) and its engineered variants when used as fusion tags in recombinant proteins. These antibodies typically detect a broad spectrum of RFP variants including:

• Discosoma-derived variants: DsRed, DsRed2, mCherry, tdTomato, mRFP, mPlum, mStrawberry, mOrange

• Entacmaea-derived variants: TagRFP, TagBFP, mKate2, mRuby2

• Synthetic variants: mScarlet

RFP is a 25-27 kDa fluorescent protein originally isolated from sea anemone (Discosoma sp.) that emits red fluorescence when excited by appropriate wavelengths (typically around 558 nm excitation, 593 nm emission) .

What applications are RFP-tag polyclonal antibodies suitable for?

RFP-tag polyclonal antibodies can be utilized in multiple experimental applications with different recommended dilutions:

The versatility of RFP antibodies makes them valuable tools for tracking RFP-tagged proteins in various experimental contexts .

How should RFP-tag polyclonal antibodies be stored and handled?

For optimal performance and longevity:

• Store concentrated antibody at -20°C

• Avoid repeated freeze-thaw cycles by making small aliquots

• Typical storage buffer includes PBS (pH 7.4) with 50% glycerol and 0.02-0.05% sodium azide as preservative

• Antibodies remain stable for approximately one year when properly stored

• Some antibodies may be stable for several weeks at 4°C as undiluted liquid

• Always centrifuge product if not completely clear after standing at room temperature

Proper storage significantly impacts antibody performance and experimental reproducibility .

How should I choose between polyclonal, monoclonal, and recombinant RFP antibodies for my research?

The choice depends on your specific experimental requirements:

Polyclonal RFP antibodies:

• Recognize multiple epitopes on RFP

• Higher sensitivity for detecting low-abundance RFP-tagged proteins

• Better for cross-linked/fixed tissues where some epitopes may be masked

• Useful for preliminary investigations

• May show higher background and lot-to-lot variability

Monoclonal RFP antibodies:

• Recognize a single epitope on RFP

• Highly specific with minimal cross-reactivity

• Lower background

• Consistent performance between lots

• May have reduced sensitivity compared to polyclonals

• Risk of epitope loss during fixation/processing

Recombinant "Superclonal" RFP antibodies:

• Contain defined mixture of multiple recombinant monoclonal antibodies

• Combine sensitivity of polyclonals with specificity of monoclonals

• Minimal lot-to-lot variability

• Excellent for multiplex experiments and long-term studies

For resource-intensive or long-term studies requiring consistent results, choose monoclonal or recombinant antibodies. For detecting low abundance targets or in cross-linked tissues, polyclonals may be preferable .

What controls should I include when using RFP-tag polyclonal antibodies?

Proper controls are essential for validating RFP antibody specificity:

Positive controls:

• Lysate or tissue expressing known RFP-tagged proteins

• Purified RFP protein (various concentrations for sensitivity assessment)

• RFP variants (mCherry, tdTomato, etc.) to confirm cross-reactivity

Negative controls:

• Non-transfected/wild-type samples

• Samples expressing different fluorescent proteins (e.g., GFP)

• Secondary antibody-only control (omitting primary RFP antibody)

• Pre-absorbed antibody control using excess antigen

Validation approaches:

• Compare antibody signal with direct RFP fluorescence

• Confirm specificity by detecting proteins of expected molecular weight

• Cross-validate with different detection methods (IF, WB, etc.)

• Test for non-specific binding to E. coli extracts (reported with some RFP antibodies) .

What are the recommended dilutions and protocols for Western blot using RFP-tag polyclonal antibodies?

Western Blot Protocol for RFP-tag Detection:

• Sample Preparation:

  • Lyse cells in appropriate buffer containing protease inhibitors

  • Denature samples by heating at 95°C for 5 minutes in loading buffer

  • Load 20-50 μg of total protein per lane

• Gel Electrophoresis and Transfer:

  • Separate proteins on 10-12% SDS-PAGE

  • Transfer to PVDF or nitrocellulose membrane

  • Verify transfer with reversible protein stain (optional)

• Antibody Incubation:

  • Block membrane with 3-5% BSA or non-fat milk for 1 hour at room temperature

  • Incubate with primary RFP antibody (1:1,000-1:5,000 dilution) overnight at 4°C

  • Wash 3x with TBST/PBST

  • Incubate with HRP-conjugated secondary antibody (1:10,000-1:40,000) for 1 hour at room temperature

  • Wash 3x with TBST/PBST

• Detection:

  • Apply chemiluminescent substrate

  • Expose to imaging system

  • Expected molecular weight for RFP alone: ~26-27 kDa

  • For fusion proteins: add molecular weight of target protein

This protocol has been optimized based on performance data from multiple studies .

How can I minimize artificial puncta formation when using RFP for labeling secretory pathway proteins?

Artificial puncta formation is a common issue when using RFP variants to label proteins in the secretory pathway, which can compromise experimental interpretation. Research indicates these puncta colocalize with lysosomes and are influenced by:

• RFP monomeric properties: Select engineered monomeric variants over original tetrameric DsRed

• pKa values: RFP variants with higher pKa values (>6.0) are more sensitive to pH changes in secretory compartments, increasing puncta formation

• Optimization strategies:

  • Use mOrange2, which demonstrates excellent monomeric properties, appropriate pKa, and high brightness

  • Consider TagRFP or mRuby2 as alternatives with improved performance

  • Fuse RFP to an environment-sensitive membrane protein (e.g., Orai1) to rapidly evaluate RFP fusion properties

  • Validate localization pattern with orthogonal methods (antibody staining of target protein)

  • Include proper controls showing direct RFP fluorescence versus immunostaining patterns

This approach helps distinguish between genuine protein localization and artifacts caused by RFP aggregation in acidic compartments .

What are the best practices for multiplexing RFP-tag antibodies with other fluorescent protein antibodies?

Successful multiplexing requires careful consideration of spectral overlap, antibody compatibility, and detection methods:

• Antibody selection:

  • Choose antibodies from different host species (e.g., rabbit anti-RFP, mouse anti-GFP)

  • If using same-species antibodies, consider directly conjugated antibodies

  • Verify antibodies have been cross-adsorbed against other species proteins

• Fluorophore selection:

  • Select secondary antibodies with well-separated emission spectra

  • For RFP detection alongside GFP, recommended combinations:

    • RFP detection: Far-red fluorophores (e.g., CF®640R, Alexa Fluor 647)

    • GFP detection: Blue fluorophores (e.g., CF®405M, Alexa Fluor 405)

    • This avoids spectral overlap with direct RFP/GFP fluorescence

• Sequential staining protocol:

  • Apply and detect first primary antibody

  • Block with excess unconjugated Fab fragments

  • Apply and detect second primary antibody

  • Include single-stain controls to verify specificity

• Direct conjugation approach:

  • Use directly conjugated primary antibodies (e.g., RFP conjugated to CF®640R)

  • Eliminates cross-reactivity from secondary antibodies

  • Enables same-species antibody combinations

This approach allows for clean discrimination between multiple fluorescent proteins in the same sample .

How can I optimize immunoprecipitation of RFP-tagged proteins while preserving protein-protein interactions?

Immunoprecipitation of RFP-tagged proteins requires balancing efficient capture with preservation of protein-protein interactions:

• Lysis buffer optimization:

  • For stable interactions: RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris pH 8.0)

  • For weak/transient interactions: Milder buffers (150 mM NaCl, 0.5% NP-40, 50 mM Tris pH 7.5)

  • Include protease inhibitors, phosphatase inhibitors, and 1-2 mM EDTA

• Antibody selection and concentration:

  • Use 1-5 μg antibody per 500 μg total protein

  • Recommended dilution: 1:100 for IP applications

  • Pre-clear lysate with protein A/G beads to reduce non-specific binding

• Incubation conditions:

  • For maximum capture: Overnight at 4°C with gentle rotation

  • For kinetic studies: Shorter incubations (1-4 hours) to capture transient interactions

  • Wash stringency depends on interaction strength (3-5 washes)

• Advanced approaches:

  • Crosslinking RFP antibody to beads (using dimethyl pimelimidate) to prevent antibody contamination in eluates

  • Elution with excess RFP peptide for native conditions

  • Sequential IP for complex purification

These optimizations improve the specificity and efficiency of RFP-tagged protein complex isolation while maintaining physiologically relevant interactions .

How do different RFP variants affect antibody recognition and experimental outcomes?

Different RFP variants exhibit varying properties that impact antibody recognition and experimental outcomes:

Important considerations:

• Original tetrameric DsRed exhibits strongest antibody recognition but can disrupt fusion protein function

• Monomeric variants (mCherry, mOrange2) show fewer artifacts in fusion proteins but potentially weaker antibody binding

• Tandem dimers (tdTomato) offer brightness while reducing oligomerization issues

• Synthetic variants (mScarlet) may require validation with specific antibody lots

This comparative analysis helps researchers select appropriate RFP variants based on their specific experimental requirements and antibody detection methods .

What are the methodological considerations for using RFP antibodies in tissue clearing and 3D imaging applications?

When incorporating RFP antibodies into tissue clearing and 3D imaging workflows:

• Tissue preparation and fixation:

  • Use 4% paraformaldehyde fixation (12-24h at 4°C)

  • Shorter fixation times (2-4h) may better preserve RFP fluorescence

  • Balance between fixation strength and epitope preservation

• Clearing method compatibility:

  • Organic solvent-based methods (3DISCO, iDISCO+): Destroy native RFP fluorescence; rely exclusively on antibody detection

  • Aqueous methods (CLARITY, CUBIC): Better preserve native RFP signal; allow comparison between direct fluorescence and antibody staining

  • Hyperhydration (FRUIT, ScaleS): Moderate RFP preservation; improved antibody penetration

• Antibody penetration strategies:

  • Use F(ab) or F(ab')2 fragments for better tissue penetration

  • Extend incubation times (3-7 days) with gentle agitation

  • Apply centrifugal force or pressure cycling to enhance antibody penetration

  • Consider indirect detection with multiple secondary antibodies for signal amplification

• Signal optimization:

  • Use far-red secondary antibodies to minimize tissue autofluorescence

  • Apply background reduction techniques (Sudan Black B, CuSO4 treatment)

  • Extended washing periods (2-3 days) to reduce non-specific binding

• Imaging considerations:

  • Adjust laser power to prevent bleaching of both native RFP and antibody fluorophores

  • Employ spectral unmixing to distinguish antibody signal from tissue autofluorescence

  • Use appropriate controls to distinguish between direct RFP fluorescence and antibody staining patterns

This methodological approach enables researchers to effectively utilize RFP antibodies in advanced 3D imaging applications while addressing the specific challenges of tissue clearing techniques .

What approaches can resolve contradictory results between direct RFP fluorescence and antibody detection methods?

When direct RFP fluorescence patterns differ from antibody detection results, systematic troubleshooting is necessary:

• Characterize the nature of discrepancies:

  • Map specific differences (localization, intensity, pattern)

  • Determine if differences are sample-wide or in specific subcellular regions

  • Document temporal aspects (do differences appear at specific timepoints?)

• Methodological validation:

  • Fixation effects: Compare live-cell imaging with fixed samples using different fixation protocols

    • Paraformaldehyde (4%) preserves direct fluorescence but may mask epitopes

    • Methanol improves antibody accessibility but quenches direct fluorescence

  • pH-dependent effects: RFP variants have different pH sensitivities

    • Use pH-resistant RFP variants (mCherry) for acidic compartments

    • Apply compartment-specific counterstains to identify problematic regions

  • Antibody validation:

    • Test multiple RFP antibodies targeting different epitopes

    • Perform antibody pre-absorption controls with purified RFP

    • Verify antibody performance in Western blot from the same samples

• Advanced analytical approaches:

  • Use super-resolution microscopy to resolve potential co-localization issues

  • Apply fluorescence correlation spectroscopy to analyze protein dynamics

  • Implement spectral imaging to distinguish true RFP signal from autofluorescence

  • Perform photobleaching experiments to confirm signal specificity

• Biological confirmation:

  • Use orthogonal detection methods (antibodies against the non-RFP portion of fusion protein)

  • Employ alternative tagging strategies (HaloTag, SNAP-tag) for comparison

  • Validate with endogenous protein detection when possible

  • Create point mutations in RFP to specifically disrupt antibody recognition without affecting fluorescence

This comprehensive approach helps researchers determine whether discrepancies represent technical artifacts or biologically meaningful differences between protein populations .

How can RFP antibodies be integrated with proximity labeling techniques for mapping protein interactions?

Integration of RFP antibodies with proximity labeling enables powerful protein interaction mapping:

• BioID/TurboID applications:

  • Create RFP-BioID fusion constructs for visualization and proximity labeling

  • Use RFP antibodies to verify expression and localization of the bait protein

  • Implement dual-color imaging to correlate proximity labeling with RFP localization

  • Protocol modification: Include biotin identification alongside RFP immunoprecipitation

• APEX2 integration:

  • Design RFP-APEX2 fusion proteins for combined visualization and EM-compatible labeling

  • Correlative light-electron microscopy workflow:

    • Identify RFP-positive regions by fluorescence microscopy

    • Perform DAB reaction for EM visualization

    • Confirm specific labeling with RFP antibody-gold conjugates

• Split-RFP proximity systems:

  • Generate split-RFP complementation constructs for direct visualization of protein interactions

  • Apply RFP antibodies to enhance detection sensitivity of weak interactions

  • Combined workflow:

    • Initial screening by direct fluorescence

    • Confirmation and enhancement with RFP antibody detection

    • Quantitative assessment of interaction strength

• Multiplex interaction mapping:

  • Combine RFP-based proximity labeling with orthogonal systems (HaloTag, SNAP-tag)

  • Use differentially conjugated antibodies to visualize multiple interaction networks

  • Implementation of sequential epitope detection for highly multiplexed imaging

These integrative approaches leverage the specificity of RFP antibodies to enhance the sensitivity and resolution of proximity labeling techniques, enabling more comprehensive mapping of protein interaction networks .

What are the latest developments in using RFP antibodies for intravital imaging and in vivo applications?

Recent advances in RFP antibody applications for intravital and in vivo imaging include:

• Antibody format innovations:

  • Near-infrared fluorophore conjugated antibodies for deeper tissue penetration

  • Smaller antibody formats (nanobodies, VHH domains) with enhanced tissue penetration

  • Site-specific conjugation methods to improve fluorophore orientation and brightness

• In vivo delivery systems:

  • Nanoparticle encapsulation of RFP antibodies for targeted delivery

  • Blood-brain barrier penetrating antibody derivatives for neuroimaging

  • Conjugation to cell-penetrating peptides for improved cellular uptake

  • Implementation protocols typically involve:

    • In vivo administration (IV, intraperitoneal, or intracranial)

    • Extended circulation time (3-12 hours)

    • Imaging window preparation or transcranial imaging

• Multimodal imaging strategies:

  • Dual-labeled antibodies (fluorescence + MRI/PET/CT contrast agents)

  • Photoacoustic imaging compatibility through specific near-infrared fluorophores

  • Integrating optical and non-optical imaging modalities for comprehensive visualization

• Long-term longitudinal imaging:

  • Photostable fluorophore conjugates (CF®640R, CF®680R) for reduced photobleaching

  • Controlled-release systems for sustained antibody availability

  • Identification of optimal imaging windows and intervals to monitor dynamic processes

• Quantitative intravital applications:

  • Calibrated imaging approaches for protein quantification in vivo

  • Ratiometric measurements comparing direct RFP fluorescence to antibody signal

  • Computational approaches to account for tissue-specific signal attenuation

These developments expand the utility of RFP antibodies beyond traditional fixed tissue applications, enabling researchers to monitor protein dynamics in living organisms with enhanced specificity and sensitivity .